Cefixime-resistant Neisseria gonorrhoeae in the UK: a time to reflect on practice and recommendations
Cefixime-resistant Neisseria gonorrhoeae in the UK: a time to reflect on practice and recommendations
复制标题
DOI：
10.1258/ijsa.2009.009191
复制
发表时间：
2011-05-01
影响因子：
1.4
通讯作者：
Rooney, G.
中科院分区：
文献类型：
--
作者：
Forsyth, S.;Penney, P.;Rooney, G.
一名40岁男性尿道淋病患者口服400 mg头孢克肟治疗无效。治疗后菌株的实验室分离显示最小抑制浓度>= 0.25 mg/L，这是英国以前没有记录的头孢克肟耐受水平。该病例说明了对所有淋病治疗后患者进行评估的重要性，以便确定治疗失败和抗生素耐药性。至关重要的是，淋病文化继续尝试从所有感染的个人，使准确的诊断和抗生素敏感性。我们还建议实验室定期检测头孢克肟的敏感性，因为它是淋病最常用的治疗方法之一。
A 40-year-old man who has sex with men (MSM) with urethral gonorrhoea failed to respond to treatment with 400 mg cefixime orally. Laboratory isolation of the post-treatment strain showed a minimum inhibitory concentration of >= 0.25 mg/L, which is a level of tolerance to cefixime that has not been previously documented in the UK. This case illustrates the importance of assessing all patients after treatment for gonorrhoea so that treatment failure and antibiotic resistance can be identified. It is vital that gonorrhoea culture continues to be attempted from all infected individuals to enable accurate diagnosis and antibiotic sensitivities. We also recommend that laboratories test for cefixime sensitivity routinely, given that it is one of the most commonly prescribed treatments for gonorrhoea.